Abstract
Background: In experimental autoimmune encephalomyelitis, inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors resulted in a significantly ameliorated disease course. We evaluated the effects of ARBs and ACE inhibitors on the efficacy of interferon beta-1b in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: In this post hoc analysis of the BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) study, clinical and MRI end points were compared between patients treated with interferon beta-1b 250 or 500 μg and concomitant ARBs or ACE inhibitors and patients treated with interferon beta-1b 250 or 500 μg only (reference group). Results: Patients in the ARB group (n = 22) tended to have a higher relapse rate (0.48 vs. 0.23, p = 0.051) and a higher number of new gadolinium-enhancing lesions (0.6 vs. 0.3, p = 0.057) than patients in the reference group. Patients in the ACE inhibitor group (n = 49) also tended to have a higher relapse rate (0.29 vs. 0.22, p = 0.357). No differences were observed for the other end points. Conclusion: In the BEYOND study cohort, a concomitant medication with ARBs or ACE inhibitors did not have a beneficial effect in patients with RRMS treated with interferon beta-1b. As patients appeared to have a higher relapse rate, our results warrant further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 173-179 |
| Number of pages | 7 |
| Journal | European Neurology |
| Volume | 71 |
| Issue number | 3-4 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Angiotensin receptor blockers
- Angiotensin-converting enzyme inhibitors
- BEYOND study
- Cardiovascular comorbidity
- Hypertension
- Immune system
- Interferon beta
- Multiple sclerosis
- Renin-angiotensin system
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b : A post hoc analysis of the beyond study. / Doerner, M.; Beckmann, K.; Knappertz, V.; Kappos, L.; Hartung, H. P.; Filippi, M.; O'Connor, P. W.; Arnason, B.; Cook, S.; Jeffery, D.; Comi, G.; Limmroth, V.
In: European Neurology, Vol. 71, No. 3-4, 2014, p. 173-179.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b
T2 - A post hoc analysis of the beyond study
AU - Doerner, M.
AU - Beckmann, K.
AU - Knappertz, V.
AU - Kappos, L.
AU - Hartung, H. P.
AU - Filippi, M.
AU - O'Connor, P. W.
AU - Arnason, B.
AU - Cook, S.
AU - Jeffery, D.
AU - Comi, G.
AU - Limmroth, V.
PY - 2014
Y1 - 2014
N2 - Background: In experimental autoimmune encephalomyelitis, inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors resulted in a significantly ameliorated disease course. We evaluated the effects of ARBs and ACE inhibitors on the efficacy of interferon beta-1b in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: In this post hoc analysis of the BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) study, clinical and MRI end points were compared between patients treated with interferon beta-1b 250 or 500 μg and concomitant ARBs or ACE inhibitors and patients treated with interferon beta-1b 250 or 500 μg only (reference group). Results: Patients in the ARB group (n = 22) tended to have a higher relapse rate (0.48 vs. 0.23, p = 0.051) and a higher number of new gadolinium-enhancing lesions (0.6 vs. 0.3, p = 0.057) than patients in the reference group. Patients in the ACE inhibitor group (n = 49) also tended to have a higher relapse rate (0.29 vs. 0.22, p = 0.357). No differences were observed for the other end points. Conclusion: In the BEYOND study cohort, a concomitant medication with ARBs or ACE inhibitors did not have a beneficial effect in patients with RRMS treated with interferon beta-1b. As patients appeared to have a higher relapse rate, our results warrant further investigation.
AB - Background: In experimental autoimmune encephalomyelitis, inhibition of the renin-angiotensin system with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors resulted in a significantly ameliorated disease course. We evaluated the effects of ARBs and ACE inhibitors on the efficacy of interferon beta-1b in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: In this post hoc analysis of the BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) study, clinical and MRI end points were compared between patients treated with interferon beta-1b 250 or 500 μg and concomitant ARBs or ACE inhibitors and patients treated with interferon beta-1b 250 or 500 μg only (reference group). Results: Patients in the ARB group (n = 22) tended to have a higher relapse rate (0.48 vs. 0.23, p = 0.051) and a higher number of new gadolinium-enhancing lesions (0.6 vs. 0.3, p = 0.057) than patients in the reference group. Patients in the ACE inhibitor group (n = 49) also tended to have a higher relapse rate (0.29 vs. 0.22, p = 0.357). No differences were observed for the other end points. Conclusion: In the BEYOND study cohort, a concomitant medication with ARBs or ACE inhibitors did not have a beneficial effect in patients with RRMS treated with interferon beta-1b. As patients appeared to have a higher relapse rate, our results warrant further investigation.
KW - Angiotensin receptor blockers
KW - Angiotensin-converting enzyme inhibitors
KW - BEYOND study
KW - Cardiovascular comorbidity
KW - Hypertension
KW - Immune system
KW - Interferon beta
KW - Multiple sclerosis
KW - Renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=84892753750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892753750&partnerID=8YFLogxK
U2 - 10.1159/000355530
DO - 10.1159/000355530
M3 - Article
C2 - 24457374
AN - SCOPUS:84892753750
VL - 71
SP - 173
EP - 179
JO - European Neurology
JF - European Neurology
SN - 0014-3022
IS - 3-4
ER -